

U.S. House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 25 AM 11:58

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

|  |                           |                   |                         |
|--|---------------------------|-------------------|-------------------------|
| 1. Registrant Name<br>Health Policy Alternatives, Inc.   |                           |                   |                         |
| 2. Address <input type="checkbox"/> Check if different than previously reported<br>400 North Capitol St. NW, Suite 799 |                           |                   |                         |
| 3. Principal Place of Business (if different from line 2)<br>City: Washington State/Zip (or Country) DC 20001          |                           |                   |                         |
| 4. Contact Name<br>Thomas A. Ault  | Telephone<br>202-737-3390 | E-mail (optional) | 5. Senate ID #<br>17875 |
| 7. Client Name <input type="checkbox"/> Self<br>Pharmaceutical Research & Manufacturers of America                     |                           |                   | 6. House ID #<br>31262  |

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐
9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☒ ⇒ Termination Date 7-31-04

11. No Lobbying

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13****12. Lobbying Firms**

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐
 \$10,000 or more ☒ ⇒ \$ 20,000  
 Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

**13. Organizations**

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐
 \$10,000 or more ☐ ⇒ \$ \_\_\_\_\_  
 Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

☐ Method A. Reporting amounts using LDA definition☐ Method B. Reporting amounts under section 603 Internal Revenue Code☐ Method C. Reporting amounts under section 162 Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

LD-2 (REV. 6/98)

P/

Registrant Name Health Policy Alternatives Client Name Pharmaceutical Research & Manuf

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues


Technical assistance on various issues related to Medicare coverage and reimbursement of pharmaceuticals, including the Medicare outpatient PPS

17. House(s) of Congress and Federal agencies contacted ☒ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|------|---|
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |
|      |   |

9. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature  Date 2/14/05

Printed Name and Title Thomas A. Ault, Principal

Form LD-2 (Rev. 6/98)

Page 2